Quoin Pharmaceuticals, Ltd. (QNRX) Financial Statements
Free cash flow over the same period: -$15.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
QNRXQuoin Pharmaceuticals, Ltd.Follow QNRX — free
—
Price chart with a free account
- Market cap
- 282.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 1.6 | 2.7 | 3.3 | 3.6 | 9.8 | 12.4 | |
| Pre-tax income | -21.5 | -9.4 | -8.7 | -9.0 | -15.8 | -18.7 | |
| Net income | -21.5 | -9.4 | -8.7 | -9.0 | -15.8 | -18.7 | |
| Diluted EPS ($) | -0.01 | — | — | — | — | — | |
| Diluted shares (mn) | 1584.9 | — | — | — | — | — |
USD millions · SEC XBRL
Quoin Pharmaceuticals, Ltd. — questions
- What is Quoin Pharmaceuticals, Ltd.'s net income?
- -$18.7M over the twelve months to 2026-06-30.
- What is Quoin Pharmaceuticals, Ltd.'s free cash flow?
- -$15.3M over the twelve months to 2026-06-30.
Every figure on this page comes from Quoin Pharmaceuticals, Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.